$39.70
6.29% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Praxis Precision Medicines Inc Stock price

$39.70
+4.36 12.34% 1M
-33.98 46.12% 6M
-37.26 48.41% YTD
-5.31 11.80% 1Y
-120.95 75.29% 3Y
-245.30 86.07% 5Y
-245.30 86.07% 10Y
Nasdaq, Closing price Tue, May 20 2025
+2.35 6.29%
ISIN
US74006W1080
Symbol
PRAX
Sector
Industry

Key metrics

Market capitalization $808.65m
Enterprise Value $481.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 59.33
P/S ratio (TTM) P/S ratio 99.59
P/B ratio (TTM) P/B ratio 1.84
Revenue growth (TTM) Revenue growth 270.02%
Revenue (TTM) Revenue $8.12m
EBIT (operating result TTM) EBIT $-233.01m
Free Cash Flow (TTM) Free Cash Flow $-163.88m
Cash position $327.99m
EPS (TTM) EPS $-10.71
P/E forward negative
P/S forward 723.01
EV/Sales forward 430.71
Short interest 8.72%
Show more

Is Praxis Precision Medicines Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Praxis Precision Medicines Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Praxis Precision Medicines Inc forecast:

11x Buy
92%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Praxis Precision Medicines Inc forecast:

Buy
92%
Sell
8%

Financial data from Praxis Precision Medicines Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
8.12 8.12
269% 269%
100%
- Direct Costs 0.29 0.29
66% 66%
4%
7.83 7.83
484% 484%
96%
- Selling and Administrative Expenses 54 54
28% 28%
669%
- Research and Development Expense 186 186
111% 111%
2,294%
-233 -233
80% 80%
-2,866%
- Depreciation and Amortization 0.29 0.29
66% 66%
4%
EBIT (Operating Income) EBIT -233 -233
79% 79%
-2,870%
Net Profit -213 -213
70% 70%
-2,618%

In millions USD.

Don't miss a Thing! We will send you all news about Praxis Precision Medicines Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Praxis Precision Medicines Inc Stock News

Neutral
GlobeNewsWire
18 days ago
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors grant...
Neutral
GlobeNewsWire
19 days ago
On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen Vormatrigine continues to generate a best-in-class safety profile with new data demonstrating no food effect and h...
Neutral
GlobeNewsWire
about one month ago
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:...
More Praxis Precision Medicines Inc News

Company Profile

Praxis Precision Medicines, Inc. is a clinical-stage genetic neuroscience company that develops therapies for patients and families affected by complex and debilitating brain disorders. The company was founded by Kiran Reddy, David Goldstein and Steven Petrou on September 22, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Marcio Souza
Employees 116
Founded 2015
Website www.praxismedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today